A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, dose-finding study of tivozanib administered in
combination with capecitabine. During the dose-escalation portion, sequential cohorts of
subjects with advanced solid tumors will be enrolled in order to establish the maximum
tolerated dose (MTD). If the MTD is not reached, the recommended Phase 2 dose (RP2D) will be
determined. In the expansion cohort, subjects with locally advanced or metastatic breast or
colon cancer will be enrolled at MTD (or RP2D) to further evaluate safety and activity of
this combination in these tumor types.